Intermede Investment Partners LTD Biogen Inc. Transaction History

Intermede Investment Partners LTD

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2019 May 01, 2019	SELL	$216.71 - $338.96 $22.6 Million - $35.3 Million	-104,117 Closed	0 $0
Q4 2018 Feb 14, 2019	SELL	$278.5 - $352.75 $7.52 Million - $9.52 Million	-26,996 Reduced 20.59%	104,117 $31.3 Million
Q3 2018 Oct 29, 2018	BUY	$293.51 - $383.83 $1.78 Million - $2.33 Million	6,062 Added 4.85%	131,113 $46.3 Million
Q2 2018 Aug 08, 2018	SELL	$257.52 - $306.91 $1.08 Million - $1.29 Million	-4,193 Reduced 3.24%	125,051 $36.3 Million
Q1 2018 May 01, 2018	SELL	$260.13 - $367.91 $2.01 Million - $2.84 Million	-7,713 Reduced 5.63%	129,244 $35.4 Million
Q4 2017 Jan 19, 2018	BUY	$307.64 - $344.58 $1.98 Million - $2.22 Million	6,450 Added 4.94%	136,957 $43.6 Million
Q3 2017 Oct 24, 2017	BUY	$281.15 - $329.69 $36.7 Million - $43 Million	130,507	130,507 $40.9 Million

1,037

126M

1.13M

1.43M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $22.7B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Intermede Investment Partners LTD, based on Form 13F filings with the SEC.

Stay updated on Intermede Investment Partners LTD with notifications on news.